ClinicalTrials.gg
Active, not recruitingNCT02952508CLOVER-WaMUpdated Mar 18, 2026

Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom

A Phase 2 interventional study of Iopofosine I 131 single dose and Iopofosine I 131 multiple dose in Waldenstrom Macroglobulinemia, Multiple Myeloma and Chronic Lymphocytic Leukemia, sponsored by Cellectar Biosciences, Inc.. Active, not recruiting at 52 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-03-18.

Sponsored by Cellectar Biosciences, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jun 2026, 4 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 419 studies in Waldenstrom Macroglobulinemia with a site in United States — 34 open to participants now, 57 under way, 1 of them phase 3. Waldenstrom Macroglobulinemia · United States.

Planned enrollment
46th of 365
120 · median 37
Started
2017
with 15 others
Phase 2
161 of 419
9 open now
Primary completion
2026-06
later than 13 of 54 live
Registered
344th of 419
by date

Among the 419 studies in Waldenstrom Macroglobulinemia with a site in United States, this one is the 46th largest by planned enrollment of the 365 interventional ones that give a count, is one of 16 that started in 2017, is one of 161 in phase 2, reaches primary completion later than 13 of the 54 other live ones, and was the 344th registered.

Waldenstrom Macroglobulinemia

524 studies on the registry are indexed under Waldenstrom Macroglobulinemia; 61 are open to participants now.

Browse Waldenstrom Macroglobulinemia studies →

Open to participants now

34 of the 419 studies in Waldenstrom Macroglobulinemia with a site in United States are open now. Recruiting first, the newest first:

29 more — sign in →

All 34 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 47 Waldenstrom Macroglobulinemia studies recruiting now, 43 (91%) set no upper age limit and 1 (2%) stops at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 419 studies in Waldenstrom Macroglobulinemia with a site in United States, or all of them as a file.
02

Study summary

Part A of this study evaluates iopofosine I 131 (CLR 131) in patients with select B-cell malignancies (multiple myeloma( MM), indolent chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL), lymphoplasmacytic lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), marginal zone lymphoma (MZL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and central nervous system lymphoma (CNSL) who have been previously treated with standard therapy for their underlying malignancy. Part B (CLOVER-WaM) is a pivotal efficacy study evaluating IV administration of iopofosine I 131 in patients with WM that have received at least two prior lines of therapy.

Read the detailed description

B-cell malignancies represent a diverse collection of diseases and, taken together, make up the majority of hematologic malignancies. B-cell lymphomas represent the largest percentage of these neoplasms, and the relapsed and/or refractory B-cell lymphomas have proven very difficult to treat. Patients that have failed prior therapy, including WM patients, represent a very challenging patient population with significantly reduced life-expectancy.

Iopofosine I 131 is a targeted radiotherapeutic that exploits the selective uptake and retention of Cellectar's proprietary phospholipid ethers (PLEs) by malignant cells. Cellectar Biosciences' novel cancer-targeted small-molecule compound is radiolabeled with the radioisotope iodine-131 (I-131) which has previously been used approved for use in select tumors. Iopofosine I 131 has been evaluated in over 80 xenograft and spontaneous (transgenic) tumor models where it was demonstrated to be effective in eliminating tumors.

Based on the critical unmet medical need for effective agents with novel mechanisms of action in B-cell malignancies, Cellectar Biosciences has chosen to expand this ongoing study to assess iopofosine I 131 in a pivotal expansion cohort in Waldenstrom's Macroglobulinemia patients that have received at least two prior lines of therapy.

03

Conditions studied

  • Waldenstrom Macroglobulinemia
  • Multiple Myeloma
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Lymphoplasmacytic Lymphoma
  • Marginal Zone Lymphoma
  • Mantle Cell Lymphoma
  • Diffuse Large B Cell Lymphoma
  • Central Nervous System Lymphoma

Keywords

  • Waldenstrom Macroglobulinemia
  • Non-Hodgkin Lymphoma
  • NHL
  • Relapsed
  • Refractory
  • Novel class
  • Pivotal
  • Phase 3
  • Hematologic disease
  • Neoplasm
  • Plasma cell neoplasms
  • Paraproteinemias
  • Lymphoma
  • Immunoproliferative disorder
  • Blood protein disorders
  • Lymphoproliferative disorders
  • Antineoplastic agents
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

[CLOVER-1] Inclusion Criteria: All Patients

  • or cytologically confirmed MM; Patients with primary or secondary CNSL may be enrolled.
  • performance status of 0 to 2
  • 18 years of age or older
  • of at least 6 months
  • ≥ 75,000/µL (if full-dose anticoagulation therapy is used, platelets ≥ 100,000/µL are required)
  • WBC count ≥ 3000/µL
  • ≥ 1500/µL
  • ≥ 9 g/dL (last transfusion, if any, must be at least 1 week prior to study registration, and no transfusions are allowed between registration and dosing)
  • Estimated ≥ 30 mL/min/1.73 m2
  • (AST) and Alanine aminotransferase (ALT) ≤ 2.5 × (ULN)
  • \< 1.5 × ULN
  • (INR) \< 2.5
  • If patient is on full-dose anticoagulation therapy, the anticoagulation therapy must be reversible and reversal of the anticoagulation therapy must not be life-threatening, as judged by the Investigator
  • Patients who have undergone stem cell transplant must be at least 100 days from transplant

Patients with Multiple Myeloma

  • At least 5 prior regimens, which must include at least 1 approved proteasome inhibitor (bortezomib, carfilzomib, or ixazomib), at least 1 approved immunomodulatory agent (thalidomide, lenalidomide, or pomalidomide), and at least 1 approved monoclonal antibody (e.g., daratumumab or elotuzumab) with or without maintenance therapy, unless patients are intolerable to such agents or ineligible to receive such agents.
  • At least triple-class (refractory to a proteasome inhibitor, immunomodulatory agent, and a monoclonal antibody)
  • Progressive disease defined by any of the following:

    • 25% increase in serum M-protein from the lowest response value during (or after) last therapy and/or absolute increase in serum M-protein of ≥ 0.5 g/dL
    • 25% increase in urine M-protein from the lowest response value during (or after) last therapy and/or absolute increase in urine M-protein of ≥ 200 mg/24 h
    • 25% increase in bone marrow plasma cell percentage from the lowest response value during (or after) last therapy. Absolute bone marrow plasma cell percentage must be ≥ 10% unless prior CR when absolute bone marrow plasma cell percentage must be ≥ 5%.
    • 25% increase in serum FLC level from the lowest response value during (or after) last therapy; the absolute increase must be > 10 mg/dL
    • New onset hypercalcemia > 11.5 mg/dL
    • Failure to obtain a partial response or better to current treatment, or cannot further improve their response to current treatment
    • Appearance of new extramedullary disease
  • defined by any of the following:

    • Serum M-protein > 0.5 g/dL
    • Urine M-protein > 200 mg/24 h
    • Serum FLC assay: Involved FLC level ≥ 10 mg/dL provided serum FLC ratio is abnormal.

[CLOSED] Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma/Waldenstom Macroglobulinemia, or Marginal Zone Lymphoma

  • Prior treatment with at least 2 prior regimens, which may include chemotherapy, an approved anti-CD20 antibody with or without maintenance therapy, and an approved targeted agent, unless patients are ineligible to receive such agents
  • Patients with Helicobacter pylori+ mucosa-associated lymphoid tissue lymphoma must have received 1 prior antibiotic regimen for H pylori
  • At least 1 measurable nodal lesion with longest diameter > 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter > 10 mm. Additional parameters (e.g., measurable IgM for patients with Lymphoplasmacytic Lymphoma) may be allowed if they meet current NCCN guidelines for symptomatic disease. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.

[CLOSED] Patients with Mantle Cell Lymphoma

  • Prior treatment with at least 1 prior regimen
  • At least 1 measurable nodal lesion with longest diameter > 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter > 10 mm. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.

[CLOSED] Patients with Diffuse Large B-Cell Lymphoma

  • Relapsed or refractory to combination chemotherapy for DLBCL that contains rituximab and an anthracycline; or is intolerable to such agents. Relapsed disease is defined as either recurrence of disease after a CR or PD after achieving a partial response (PR) or SD. Refractory disease is defined as failure to achieve at least SD with any 1 or with PD ≤ 3 months of the most recent chemotherapy regimen.
  • At least 1 measurable nodal lesion with longest diameter > 15 mm or 1 measurable extranodal lesion (eg, hepatic nodule) with longest diameter > 10 mm. Patients with uptake by FDG-PET scan may be allowed with prior approval of Sponsor.

Patients with CNS Lymphoma

  • Must have -proven disease and must have received at least one prior intervention for their disease.
  • Must be at least two weeks from CNS biopsy before administration of iopofosine I 131.
  • Must have at least one lesion with enhancement on brain imaging.
  • Stable (or decreasing) dose of or anti-convulsant medication for at least 7 days prior to dosing

[CLOVER-1] Exclusion Criteria:

  • Ongoing Grade 2 or greater toxicities due to previous therapies. Stable, tolerable Grade 2 AEs (eg, neuropathy) may be allowed.
  • Prior external-beam RT resulting in greater than 20% of total bone marrow receiving greater than 20 Gy.
  • Prior total body or hemi-body irradiation. Patients who have received prior low-dose total body or hemi-body irradiation may be allowed on a case-by-case basis after discussion with Sponsor (considerations may include factors such as time since irradiation, total lifetime accumulated dose, etc.)
  • Extradural tumor in contact with the spinal cord or tumor located where swelling in response to therapy may impinge upon the spinal cord
  • For patients with CLL/SLL, LPL, or MZL, transformation to a more aggressive form of NHL
  • Ongoing chronic therapy
  • bleeding event within prior 6 months
  • Ongoing anti-platelet therapy (except low-dose aspirin [eg, 81 mg daily] for cardioprotection)
  • Anti-cancer therapy within two weeks of initial iopofosine I 131 infusion. Low dose dexamethasone for symptom management is allowed
  • Radiation therapy, chemotherapy, immunotherapy, or therapy within 2 weeks of eligibility-defining bone marrow biopsy.
  • For patients with primary or secondary CNSL, active bleeding in the tumor bed and/or uncontrolled seizure activity

[CLOVER-WaM] Inclusion Criteria

  • Histologically or cytologically confirmed WM. Patients with a diagnosis of LPL may be enrolled with prior Sponsor approval.
  • Patient has an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 to 2 (Appendix C)
  • Patient is 18 years of age or older
  • Life expectancy of at least 6 months
  • Received at least two prior lines of therapy for WM
  • Measurable IgM (above upper limit of normal) OR at least one measurable nodal lesion with longest diameter > 15 mm or one measurable extranodal lesion (e.g., hepatic nodule) with longest diameter > 10 mm

[CLOVER-WaM] Exclusion Criteria

  • Ongoing Grade 2 or greater toxicities due to previous therapies, excluding alopecia.
  • Prior external-beam RT resulting in greater than 20% of total bone marrow receiving greater than 20 Gy.
  • Prior total body or hemi-body irradiation. Patients who have received prior low-dose total body or hemi-body irradiation may be allowed on a case-by-case basis after discussion with Sponsor (considerations may include factors such as time since irradiation, total lifetime accumulated dose, etc.)
  • Patients with second in addition to WM, if the second malignancy has required therapy in the last 2 years or is not in remission; exceptions to this criterion include successfully treated non- basal cell or squamous cell skin carcinoma, or prostate cancer that does not require therapy
  • Anti-cancer therapy within two weeks of initial iopofosine I 131 infusion.
  • Need for acute treatment of WM (e.g., those with hyperviscosity)
Terms in these criteria, in plain language(21)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Iopofosine I 131, intravenous administration WM

    Iopofosine I 131 in Waldenstroms Macroglobulinemia

    Drug: Iopofosine I 131 single dose · Drug: Iopofosine I 131 multiple dose · Drug: Iopofosine I 131 fractionated dose

  • Experimental
    Iopofosine I 131, intravenous administration MM

    Iopofosine I 131 in Multiple Myeloma

    Drug: Iopofosine I 131 single dose · Drug: Iopofosine I 131 multiple dose · Drug: Iopofosine I 131 fractionated dose

  • Experimental
    Iopofosine I 131, intravenous administration CNS Lymphoma

    Iopofosine I 131 in Central Nervous System Lymphoma

    Drug: Iopofosine I 131 fractionated dose

  • Experimental
    Iopofosine I 131 intravenous administration NHL [CLOSED]

    Iopofosine I 131 in Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, and Diffuse Large B-Cell Lymphoma

    Drug: Iopofosine I 131 single dose · Drug: Iopofosine I 131 multiple dose · Drug: Iopofosine I 131 fractionated dose

Interventions

06

What researchers measure

Primary outcomes

  1. Part A [CLOVER-1] Clinical benefit rate

    Response assessment per International Uniform Response Criteria for Multiple Myeloma; Lugano Criteria for lymphoma; International Workshop on Chronic Lymphocytic Leukemia for CLL; VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment; or 2005 Response Criteria for CNS Lymphoma

    Time frame: 84 days

  2. Part B [CLOVER-WaM] Major Response Rate

    Response assessment per criteria modified from VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment

    Time frame: 12 months

Secondary outcomes

  1. Part A [CLOVER-1] Overall Response Rate

    Response assessment per International Uniform Response Criteria for Multiple Myeloma; Lugano Criteria for lymphoma; International Workshop on Chronic Lymphocytic Leukemia for CLL; VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment; or 2005 Response Criteria for CNS Lymphoma

    Time frame: 135 days

  2. Part A [CLOVER-1] Progression Free Survival

    Response assessment per International Uniform Response Criteria for Multiple Myeloma; Lugano Criteria for lymphoma; International Workshop on Chronic Lymphocytic Leukemia for CLL; VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment; or 2005 Response Criteria for CNS Lymphoma

    Time frame: 135 days

  3. Part A [CLOVER-1] Time to Next Treatment

    Response assessment per International Uniform Response Criteria for Multiple Myeloma; Lugano Criteria for lymphoma; International Workshop on Chronic Lymphocytic Leukemia for CLL; VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment; or 2005 Response Criteria for CNS Lymphoma

    Time frame: 3 years

  4. Part A [CLOVER-1] Overall Survival

    Response assessment per International Uniform Response Criteria for Multiple Myeloma; Lugano Criteria for lymphoma; International Workshop on Chronic Lymphocytic Leukemia for CLL; VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment; or 2005 Response Criteria for CNS Lymphoma

    Time frame: 135 days

  5. Part A [CLOVER-1] Duration of Response

    Response assessment per International Uniform Response Criteria for Multiple Myeloma; Lugano Criteria for lymphoma; International Workshop on Chronic Lymphocytic Leukemia for CLL; VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment; or 2005 Response Criteria for CNS Lymphoma

    Time frame: 135 days

  6. Part B [CLOVER-WaM] Overall Response Rate

    Response assessment per criteria modified from VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment

    Time frame: 135 days

  7. Part B [CLOVER-WaM] Treatment Free Survival

    Response assessment per criteria modified from VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment

    Time frame: 135 days

  8. Part B [CLOVER-WaM] Duration of Response

    Response assessment per criteria modified from VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment

    Time frame: 135 days

  9. Part B [CLOVER-WaM] Clinical Benefit Rate

    Response assessment per criteria modified from VIth Waldenstrom's Macroglobulinemia Criteria for Response Assessment

    Time frame: 135 days

07

Study locations

52 sites
  • Cellectar Biosciences site
    Los Angeles, California 90095, United States
  • Cellectar Biosciences site
    Redlands, California 92373, United States
  • Cellectar Biosciences site
    Washington D.C., District of Columbia 20007, United States
  • Cellectar Biosciences site
    Jacksonville, Florida 32224, United States
  • Cellectar Biosciences site
    Miami, Florida 33165, United States
  • Cellectar Biosciences site
    Tampa, Florida 33612, United States
  • Cellectar Biosciences
    Atlanta, Georgia 30332, United States
  • Cellectar Biosciences site
    Maywood, Illinois 60153, United States
  • Cellectar Biosciences site
    Warrenville, Illinois 60555, United States
  • Cellectar Biosciences site
    Westwood, Kansas 66205, United States
  • Cellectar Biosciences site
    New Orleans, Louisiana 70121, United States
  • Cellectar Biosciences site
    Baltimore, Maryland 21287, United States
  • Cellectar Biosciences
    Bethesda, Maryland 20817, United States
  • Cellectar Biosciences site
    Boston, Massachusetts 02215, United States
  • Cellectar Biosciences
    North Bergen, New Jersey 07047, United States
  • Cellectar Biosciences site
    Buffalo, New York 14263, United States
  • Cellectar Biosciences site
    New York, New York 10065, United States
  • Cellectar Biosciences site
    Rochester, New York 14642, United States
  • Cellectar Biosciences site
    Durham, North Carolina 27705, United States
  • Cellectar Biosciences
    Canton, Ohio 44718, United States
  • Cellectar Biosciences site
    Cincinnati, Ohio 45219, United States
  • Cellectar Biosciences Site
    Charleston, South Carolina 29425, United States
  • Cellectar Biosciences
    Greenville, South Carolina 29605, United States
  • Cellectar Biosciences site
    Knoxville, Tennessee 37920, United States
  • Cellectar Biosciences site
    Dallas, Texas 75246, United States
  • Cellectar Biosciences site
    Dallas, Texas 75390, United States
  • Cellectar Biosciences site
    Houston, Texas 77030, United States
  • Cellectar Biosciences site
    Seattle, Washington 98109, United States
  • Cellectar Biosciences site
    Madison, Wisconsin 53792, United States
  • Cellectar Biosciences site
    Concord, New South Wales 2139, Australia
  • Cellectar Biosciences
    Adelaide, South Australia 5000, Australia
  • Cellectar Biosciences
    Salvador, Estado de Bahia 40050-410, Brazil
  • Cellectar Biosciences
    Curitiba, Paraná 80810-050, Brazil
  • Cellectar Biosciences
    Porto Alegre, RioGrande Do Sul 90035-903, Brazil
  • Cellectar Biosciences
    Blumenau, Santa Catarina 89010-340, Brazil
  • Cellectar Biosciences Site
    Hradec Králové, 500 05, Czechia
  • Cellectar Biosciences
    Helsinki, 00029, Finland
  • Cellectar Biosciences
    Pessac, 33600, France
  • Cellectar Biosciences
    Poitiers, 86021, France
  • Cellectar Biosciences site
    Athens, 115 28, Greece
  • Cellectar Biosciences Site
    Rio, Greece
  • Cellectar Biosciences Site
    Jerusalem, Israel
  • Cellectar Biosciences
    Barcelona, 08036, Spain
  • Cellectar Biosciences site
    Barcelona, 08908, Spain
  • Cellectar Biosciences
    Madrid, 28027, Spain
  • Cellectar Biosciences
    Madrid, 28040, Spain
  • Cellectar Biosciences
    Salamanca, 37007, Spain
  • Cellectar Biosciences site
    Zaragoza, 50009, Spain
  • Cellectar Biosciences
    Ankara, 06620, Turkey (Türkiye)
  • Cellectar Biosciences
    Bornova, 35100, Turkey (Türkiye)
  • Cellectar Biosciences
    Istanbul, 34093, Turkey (Türkiye)
  • Cellectar Biosciences site
    London, NW1 2PG, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2017 (actual). Primary completion is estimated for Jun 2026, 106 months after the start.

Of 66 phase 2 interventional studies under Waldenstrom Macroglobulinemia, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 103. This study's planned 106 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 28, 2016
First posted
Nov 2, 2016
StartActual
Jul 26, 2017
Primary completionEst.
Jun 22, 2026
CompletionEst.
Dec 22, 2027
Last update
Mar 18, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 18, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02952508
Lead sponsor
Cellectar Biosciences, Inc.
Responsible party
Sponsor
First posted
Nov 2, 2016
Start date
Jul 26, 2017
Primary completion
Jun 22, 2026 (estimated)
Completion
Dec 22, 2027 (estimated)
Last update
Mar 18, 2026

Study contacts

Jarrod Longcor
study director · Cellectar Biosciences

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: CLR1404

Start the discussion